Hemorrhoids are more common than most people admit, yet only 4.4% of the global population is estimated to have them at any given time. At the same time, 40% of people who show up for a proctology consultation end up having hemorrhoids, and about 1 in 5 adults report constipation symptoms over the last year which can tilt the odds further. We will look at what happens next, from fiber dosing and sitz bath timing to office procedures like rubber band ligation and stapled hemorrhoidopexy.
Key Takeaways
- 4.4% of the global population has hemorrhoids at any given time (2018 global estimate).
- 40% of people who undergo a proctology consultation have hemorrhoids (cross-sectional clinical data).
- 3%–5% of adults report hemorrhoids or related symptoms (US prevalence range cited in clinical references).
- In hemorrhoid management, sitz baths are typically performed for 10–15 minutes per session, with multiple sessions per day in clinical patient instructions (time quantity from clinical guidance).
- Common oral fiber supplement dosing for hemorrhoid symptom control is often 5–10 g/day, which is within trial and labeling ranges for stool softening (fiber dosing quantified in clinical guidance).
- Topical hydrocortisone in hemorrhoid treatment regimens is used at 1% strength products (common OTC prescription topical concentration).
- 1.3 million outpatient visits in the US in 2016 involved hemorrhoid-related diagnoses/procedures (national outpatient encounter estimates).
- In a 2019 US claims study, hemorrhoidectomy represented the smallest segment among hemorrhoid treatments, while office-based interventions accounted for a larger share (claims-based market share split).
- Excisional hemorrhoidectomy has reported recurrence rates generally below 5% in long-term follow-up cohorts (reported recurrence ranges in clinical literature).
- Rubber band ligation achieved symptom improvement in 70% of patients in one randomized trial of grade II–III internal hemorrhoids.
- A Cochrane review reported that office-based treatments for internal hemorrhoids generally have short-term symptom benefits, with measured outcomes across trials (pooled response rates).
- The market for anorectal hemorrhoid treatments is a subset of the broader colorectal/dermatology OTC market, and global sales are in the multi-billion-dollar range according to industry aggregations (industry-market estimate).
- The US hemorrhoids treatment market value is reported in the low-single-digit billions in at least one vendor market report (vendor estimate).
- A market report estimates the US share of the global hemorrhoids treatment market is about 30% (share quantified in vendor analysis).
- The median time to symptom improvement after office-based treatment (rubber band ligation) is typically within 1–2 weeks in clinical practice
Hemorrhoids affect millions worldwide, and fiber and office treatments can rapidly improve symptoms.
Related reading
01 · Category
Epidemiology4 stats
01
4.4% of the global population has hemorrhoids at any given time (2018 global estimate).
02
40% of people who undergo a proctology consultation have hemorrhoids (cross-sectional clinical data).
03
3%–5% of adults report hemorrhoids or related symptoms (US prevalence range cited in clinical references).
04
In a 2019–2020 US nationally representative survey, 1 in 5 adults reported constipation symptoms in the prior 12 months
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, hemorrhoids are common and likely underreported, with 4.4% of the global population affected at any given time and 3% to 5% of adults reporting symptoms, while constipation related to these issues affects about 1 in 5 adults in the US over a 12 month period.
02 · Category
Medical Therapies10 stats
01
In hemorrhoid management, sitz baths are typically performed for 10–15 minutes per session, with multiple sessions per day in clinical patient instructions (time quantity from clinical guidance).
02
Common oral fiber supplement dosing for hemorrhoid symptom control is often 5–10 g/day, which is within trial and labeling ranges for stool softening (fiber dosing quantified in clinical guidance).
03
Topical hydrocortisone in hemorrhoid treatment regimens is used at 1% strength products (common OTC prescription topical concentration).
04
In OTC hemorrhoid products, typical active ingredient concentrations for anesthetics like lidocaine are 2% in many rectal formulations (strength stated on product labeling).
05
Polyethylene glycol (PEG 3350) dosing for constipation used alongside hemorrhoid management commonly targets 17 g/day (trial-standard dosing used in constipation studies).
06
In a RCT, an oral flavonoid (diosmin/hesperidin class) improved bleeding in hemorrhoid patients, with effect quantified as a statistically significant reduction measured in symptom scores.
07
Calcium dobesilate (oral venotonic) has been studied in hemorrhoids with dosing typically 500 mg two or three times daily in clinical trials (dose quantified in study protocols).
08
A systematic review found that topical nitroglycerin is studied at 0.2%–0.4% concentrations in anorectal pain conditions; hemorrhoid-adjunct studies use similar topical concentration ranges (reviewed topical dosing ranges).
09
In stool management strategies, 25–30 g/day dietary fiber intake is commonly recommended to reduce straining, which is a risk factor for hemorrhoids (fiber intake quantified in dietary guidance).
10
Water intake recommendations associated with constipation and straining reduction are commonly 1.5–2.0 L/day in guidelines summarized in patient and clinical education documents (measurable quantity).
Interpretation
Medical Therapies Interpretation
Under Medical Therapies for hemorrhoids, symptom relief is commonly supported by specific, guideline style dosing and concentrations such as 5 to 10 g per day of fiber, 10 to 15 minute sitz baths, and topical 1% hydrocortisone, reflecting a practical, number driven approach to managing inflammation, pain, and stooling strain.
03 · Category
Healthcare Utilization2 stats
01
1.3 million outpatient visits in the US in 2016 involved hemorrhoid-related diagnoses/procedures (national outpatient encounter estimates).
02
In a 2019 US claims study, hemorrhoidectomy represented the smallest segment among hemorrhoid treatments, while office-based interventions accounted for a larger share (claims-based market share split).
Interpretation
Healthcare Utilization Interpretation
In the Healthcare Utilization picture, hemorrhoid-related care drove about 1.3 million US outpatient visits in 2016, and by 2019 claims data suggest office-based interventions made up a larger share of treatment activity than hemorrhoidectomy, which was the smallest segment.
04 · Category
Clinical Effectiveness7 stats
01
Excisional hemorrhoidectomy has reported recurrence rates generally below 5% in long-term follow-up cohorts (reported recurrence ranges in clinical literature).
02
Rubber band ligation achieved symptom improvement in 70% of patients in one randomized trial of grade II–III internal hemorrhoids.
03
A Cochrane review reported that office-based treatments for internal hemorrhoids generally have short-term symptom benefits, with measured outcomes across trials (pooled response rates).
04
Stapled hemorrhoidopexy demonstrated lower postoperative pain scores than excisional hemorrhoidectomy in a meta-analysis, with mean pain reduction measured in standard score units.
05
A systematic review found that stapled hemorrhoidopexy reduced postoperative pain compared with excisional hemorrhoidectomy, with a pooled mean difference reported across trials.
06
In a randomized trial, the median time to resume normal activity after rubber band ligation was about 1 day (trial-reported recovery timing).
07
In one meta-analysis, transanal hemorrhoidal dearterialization reduced hemorrhoid symptom scores, with improvement quantified by pooled effect sizes.
Interpretation
Clinical Effectiveness Interpretation
For clinical effectiveness, procedures like excisional hemorrhoidectomy show very low long-term recurrence generally under 5%, while office-based options such as rubber band ligation can improve symptoms in about 70% of grade II to III cases, supporting a clear overall trend that higher-intensity interventions tend to deliver faster and more reliable symptom control with low recurrence.
05 · Category
Market Size5 stats
01
The market for anorectal hemorrhoid treatments is a subset of the broader colorectal/dermatology OTC market, and global sales are in the multi-billion-dollar range according to industry aggregations (industry-market estimate).
02
The US hemorrhoids treatment market value is reported in the low-single-digit billions in at least one vendor market report (vendor estimate).
03
A market report estimates the US share of the global hemorrhoids treatment market is about 30% (share quantified in vendor analysis).
04
In 2023, the global OTC hemorrhoid treatment market was valued at about USD 1–2 billion according to an industry analyst report (market value quantified).
05
A European market analysis reports that hemorrhoid treatment demand growth is driven by an aging population, with the elderly (65+) constituting over 20% of the EU population in 2022 (demographic quantified).
Interpretation
Market Size Interpretation
For the Market Size angle, global OTC hemorrhoid treatments are estimated at about USD 1 to 2 billion in 2023 with the US accounting for roughly 30 percent of that global total, and demand appears set to keep rising in Europe as people aged 65 and over make up more than 20 percent of the EU population.
More related reading
06 · Category
Treatment Patterns3 stats
01
The median time to symptom improvement after office-based treatment (rubber band ligation) is typically within 1–2 weeks in clinical practice
02
About 75% of patients with internal hemorrhoids have bleeding as their predominant symptom
03
Hemorrhoids account for 1% of all colorectal surgery procedures in some US hospital data analyses (inpatient settings)
Interpretation
Treatment Patterns Interpretation
From a treatment patterns perspective, most patients show symptom improvement after rubber band ligation within 1 to 2 weeks, and with about 75% of internal hemorrhoid cases presenting with bleeding, the typical office based approach aligns well with the rapid response clinicians aim for.
07 · Category
Clinical Burden1 stats
01
Chronic constipation increases the odds of hemorrhoids; one study reported an odds ratio of 2.5 for hemorrhoids among people with constipation
Interpretation
Clinical Burden Interpretation
From a clinical burden perspective, chronic constipation substantially raises hemorrhoid risk, with one study finding an odds ratio of 2.5, suggesting constipation could meaningfully drive more frequent cases and related treatment needs.
08 · Category
Therapeutics3 stats
01
Guidelines recommend avoiding straining and maintaining soft stools as key management steps for hemorrhoids
02
A Cochrane review reported that dietary fiber is effective in reducing symptoms of hemorrhoids in randomized trials
03
The American Gastroenterological Association notes that lifestyle changes including fiber and adequate fluids are first-line for chronic constipation, which can reduce straining related to hemorrhoids
Interpretation
Therapeutics Interpretation
Across hemorrhoid therapeutics, the strongest theme is that conservative lifestyle measures work, with a Cochrane review of randomized trials showing dietary fiber reduces symptoms and guidelines emphasizing avoiding straining by keeping stools soft.
09 · Category
Administrative & Coding1 stats
01
The UK NICE guideline for anorectal conditions includes recommendations on managing hemorrhoids using conservative and procedural approaches
Interpretation
Administrative & Coding Interpretation
Within the Administrative and Coding category, the UK NICE guideline for anorectal conditions explicitly covers hemorrhoid management using both conservative and procedural approaches, showing that coding guidance aligns with care pathways rather than a single treatment option.
10 · Category
Industry & Markets2 stats
01
Global topical analgesic markets (relevant to hemorrhoid symptom relief categories) reached about USD 1.0 trillion in 2023 across analgesic segments in industry tracking
02
The US GI (gastrointestinal) therapies market was reported at more than USD 20 billion in 2023 by market trackers, indicating scale for related colorectal symptom products
Interpretation
Industry & Markets Interpretation
From an Industry and Markets perspective, the scale of pain and GI symptom relief is large as global topical analgesic sales hit about USD 1.0 trillion in 2023 and the US GI therapies market topped USD 20 billion, suggesting strong commercial support for hemorrhoid-related symptom care within broader colorectal treatment categories.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Sophie Moreland. (2026, February 13). Hemorrhoid Statistics. Gitnux. https://gitnux.org/hemorrhoid-statistics
MLA
Sophie Moreland. "Hemorrhoid Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hemorrhoid-statistics.
Chicago
Sophie Moreland. 2026. "Hemorrhoid Statistics." Gitnux. https://gitnux.org/hemorrhoid-statistics.
Sources & references
38 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)